Table 2 Evolution of hematologic... | American Society of Hematology

Table 2

Evolution of hematologic parameters during peg-IFNα -2a treatment

	Baseline (n = 37)	Month 1 (n = 37)	Month 2 (n = 37)	Month 3 (n = 37)	Month 6 (n = 35)	Month 12 (n = 34)	Month 18 (n = 31)	Month 24 (n = 28)	Month 30 (n = 25)
No. of phlebotomized patients	25*	3	1	1	0	0	1	1	1
No. of patients with thrombocytosis	31	21	13	5	2	1	0	0	0
No. of patients with leukocytosis	18	2	2	0	0	0	0	0	0
No. of patients with splenomegaly	13†	12	10	10	2	1	0	0	0

	Baseline (n = 37)	Month 1 (n = 37)	Month 2 (n = 37)	Month 3 (n = 37)	Month 6 (n = 35)	Month 12 (n = 34)	Month 18 (n = 31)	Month 24 (n = 28)	Month 30 (n = 25)
No. of phlebotomized patients	25*	3	1	1	0	0	1	1	1
No. of patients with thrombocytosis	31	21	13	5	2	1	0	0	0
No. of patients with leukocytosis	18	2	2	0	0	0	0	0	0
No. of patients with splenomegaly	13†	12	10	10	2	1	0	0	0

n values (in parentheses) are number of patients still in treatment.

Including 20 patients treated with phlebotomy only before inclusion and 5 newly diagnosed patients phlebotomized before starting IFN.

Splenomegaly by ultrasound examination only (n = 6) or clinical (n = 7).